Asset profile
IcoSema · Kyinsu
Peptide
Evidence outlook
Approved: Type 2 diabetes, adults insufficiently controlled on basal insulin or a GLP-1 receptor... (EU)
This approval is outside the US-scoped market view; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
130 competitors in this universe: 43 direct rivals (same mechanism and indication), 27 same-class, 60 same-indication; 34 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| IcoSema (Kyinsu): this drug | Phase 3 | Peptide | GLP-1 receptor, Insulin receptor (basal) | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Detemir (Levemir) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Glargine (Lantus / Toujeo) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Glulisine (Apidra) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Icodec (Awiqli) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Lispro (Humalog) | Approved | Peptide | Insulin receptor (basal) | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lixisenatide (Adlyxin / Lyxumia) | Approved | Peptide | GLP-1 receptor | ||
| LY2963016 (Basaglar) | Approved | Peptide | Insulin receptor (basal) | ||
| LY900014 (Lyumjev) | Approved | Peptide | Insulin receptor (basal) | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| SAR341402 | Approved | Peptide | Insulin receptor (basal) | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor |
…and 115 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
37 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.